Scholars Central

Conference abstractPublished 29 Aug 2018

Re-dosing AAV gene therapy vectors - the elephant in the room

Authors: Kei Kishimoto

Selecta Biosciences, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The immunogenicity of adeno-associated virus (AAV) vectors is a key challenge for gene therapy, particularly for systemic applications. AAV vectors are non-replicating and consequently transgene expression is expected to wane over time, particularly in pediatric patients. It would be desirable to be able to readminister AAV vectors in pediatric patients and to boost expression in patients who have inadequate transgene expression. However vector re-administration is limited by the formation of neutralizing antibodies to AAV, which mediate vector clearance and inhibit efficacy. Additionally, CD8 immunity against the AAV capsid can induce liver inflammation resulting in loss of transgene expression. We have recently developed a novel strategy to induce immune tolerance to protein biotherapeutics based on the co-administration of biodegradable synthetic vaccine particles containing rapamycin (SVP-Rapamycin; Kishimoto et al., Nature Nanotechnology, 2016, Melani et al, Nature Communication, 2018). SVP-Rapamycin has been shown to mitigate the formation of anti-drug antibodies (ADAs) against pegylated uricase enzyme in patients with hyperuricemia in an ongoing Phase 2 clinical trial. Here we demonstrate that SVP-Rapamycin added on to AAV8-base gene therapy inhibits the formation of anti-AAV8 antibodies and enables successful re-dosing of AAV8 resulting in therapeutic levels of Factor IX protein directed by a second AAV injection in both mice and nonhuman primates. The effect of SVP-Rapamycin was antigen-specific, as treated mice showed normal immune responses to subsequent challenge with other antigens. In addition, co-administration of AAV with SVP-Rapamycin effectively inhibited T-cell responses to AAV. In conclusion, SVP administration at the time of in vivo gene transfer is a promising approach to enable effective redosing of AAV vectors.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Genetic Syndromes & Gene Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Genetic Syndromes & Gene Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Kei Kishimoto”